ATAXIC: An Algorithm to Quantify Transcriptomic Perturbation Heterogeneity in Single Cancer Cells

Author:

Liu Qian123,Lu Qiqi123,Wang Xiaosheng123ORCID

Affiliation:

1. Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China

2. Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China

3. Big Data Research Institute, China Pharmaceutical University, Nanjing 211198, China

Abstract

The single-cell RNA sequencing (scRNA-seq) has recently been widely utilized to quantify transcriptomic profiles in single cells of bulk tumors. The transcriptomic profiles in single cells facilitate the investigation of intratumor heterogeneity that is unlikely confounded by the nontumor components. We proposed an algorithm (ATAXIC) to quantify the heterogeneity of transcriptomic perturbations (TPs) in single cancer cells. ATAXIC calculated the TP heterogeneity level of a single cell based on the standard deviations of the absolute z-scored gene expression values for tens of thousands of genes, reflecting the asynchronous degree of transcriptomic alterations relative to the central (mean) tendency. By analyzing scRNA-seq datasets for eight cancer types, we revealed that ATAXIC scores were likely to correlate positively with the enrichment scores of various proliferation and oncogenic signatures, DNA damage repair, treatment resistance, and unfavorable phenotypes and outcomes in cancer. The ATAXIC scores varied among different cancer types, with lung cancer and melanoma having the lowest average scores and clear cell renal cell carcinoma having the highest average scores. The low TP heterogeneity in lung cancer and melanoma could bestow relatively higher response rates to immune checkpoint inhibitors on both cancer types. In conclusion, ATAXIC is a useful algorithm to quantify the TP heterogeneity in single cancer cells, as well as providing new insights into tumor biology.

Funder

China Pharmaceutical University

Publisher

Hindawi Limited

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3